Peptostreptococcus anaerobius mediates anti-PD1 therapy resistance and exacerbates colorectal cancer via myeloid-derived suppressor cells in mice.

Journal

Nature microbiology
ISSN: 2058-5276
Titre abrégé: Nat Microbiol
Pays: England
ID NLM: 101674869

Informations de publication

Date de publication:
15 May 2024
Historique:
received: 12 01 2023
accepted: 04 04 2024
medline: 16 5 2024
pubmed: 16 5 2024
entrez: 15 5 2024
Statut: aheadofprint

Résumé

Bacteria such as the oral microbiome member Peptostreptococcus anaerobius can exacerbate colorectal cancer (CRC) development. Little is known regarding whether these immunomodulatory bacteria also affect antitumour immune checkpoint blockade therapy. Here we show that administration of P. anaerobius abolished the efficacy of anti-PD1 therapy in mouse models of CRC. P. anaerobius both induced intratumoral myeloid-derived suppressor cells (MDSCs) and stimulated their immunosuppressive activities to impair effective T cell responses. Mechanistically, P. anaerobius administration activated integrin α

Identifiants

DOI: 10.1038/s41564-024-01695-w PMID: 38750176
pubmed: 38750176
doi: 10.1038/s41564-024-01695-w
pii: 10.1038/s41564-024-01695-w
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Research Grants Council, University Grants Committee (RGC, UGC)
ID : R4032-21F, T12-703/19-R, C4039-19G

Informations de copyright

© 2024. The Author(s).

Références

Nejman, D. et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science 368, 973–980 (2020).
doi: 10.1126/science.aay9189 pubmed: 32467386 pmcid: 7757858
Yang, L., Li, A., Wang, Y. & Zhang, Y. Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy. Signal Transduct. Target. Ther. 8, 35 (2023).
doi: 10.1038/s41392-022-01304-4 pubmed: 36646684 pmcid: 9842669
Nino, J. L. G. et al. Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer. Nature 611, 810–817 (2022).
doi: 10.1038/s41586-022-05435-0
Spencer, S. P., Fragiadakis, G. K. & Sonnenburg, J. L. Pursuing human-relevant gut microbiota-immune interactions. Immunity 51, 225–239 (2019).
doi: 10.1016/j.immuni.2019.08.002 pubmed: 31433970 pmcid: 7205593
Zhou, C. B., Zhou, Y. L. & Fang, J. Y. Gut microbiota in cancer immune response and immunotherapy. Trends Cancer 7, 647–660 (2021).
doi: 10.1016/j.trecan.2021.01.010 pubmed: 33674230
Kostic, A. D. et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14, 207–215 (2013).
doi: 10.1016/j.chom.2013.07.007 pubmed: 23954159 pmcid: 3772512
Long, X. et al. Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity. Nat. Microbiol. 4, 2319–2330 (2019).
doi: 10.1038/s41564-019-0541-3 pubmed: 31501538
Zhao, L. et al. Parvimonas micra promotes colorectal tumorigenesis and is associated with prognosis of colorectal cancer patients. Oncogene 41, 4200–4210 (2022).
doi: 10.1038/s41388-022-02395-7 pubmed: 35882981 pmcid: 9439953
Kraehenbuehl, L., Weng, C. H., Eghbali, S., Wolchok, J. D. & Merghoub, T. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat. Rev. Clin. Oncol. 19, 37–50 (2022).
doi: 10.1038/s41571-021-00552-7 pubmed: 34580473
Abbott, M. & Ustoyev, Y. Cancer and the immune system: the history and background of immunotherapy. Semin. Oncol. Nurs. 35, 150923 (2019).
doi: 10.1016/j.soncn.2019.08.002 pubmed: 31526550
Baruch, E. N. et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science 371, 602–609 (2021).
doi: 10.1126/science.abb5920 pubmed: 33303685
Davar, D. et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science 371, 595–602 (2021).
doi: 10.1126/science.abf3363 pubmed: 33542131 pmcid: 8097968
Geller, L. T. et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 357, 1156–1160 (2017).
doi: 10.1126/science.aah5043 pubmed: 28912244 pmcid: 5727343
Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97–103 (2018).
doi: 10.1126/science.aan4236 pubmed: 29097493
Griffin, M. E. et al. Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy. Science 373, 1040–1046 (2021).
doi: 10.1126/science.abc9113 pubmed: 34446607 pmcid: 9503018
Tanoue, T. et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature 565, 600–605 (2019).
doi: 10.1038/s41586-019-0878-z pubmed: 30675064
Liao, W. et al. KRAS–IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer. Cancer Cell 35, 559–572 (2019).
doi: 10.1016/j.ccell.2019.02.008 pubmed: 30905761 pmcid: 6467776
Highfill, S. L. et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci. Transl. Med. 6, 237ra267 (2014).
doi: 10.1126/scitranslmed.3007974
Li, B. H., Garstka, M. A. & Li, Z. F. Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor. Mol. Immunol. 117, 201–215 (2020).
doi: 10.1016/j.molimm.2019.11.014 pubmed: 31835202
Tcyganov, E., Mastio, J., Chen, E. & Gabrilovich, D. I. Plasticity of myeloid-derived suppressor cells in cancer. Curr. Opin. Immunol. 51, 76–82 (2018).
doi: 10.1016/j.coi.2018.03.009 pubmed: 29547768 pmcid: 5943174
Medina, E. & Hartl, D. Myeloid-derived suppressor cells in infection: a general overview. J. Innate Immun. 10, 407–413 (2018).
doi: 10.1159/000489830 pubmed: 29945134 pmcid: 6784037
van Driel, B. J., Liao, G., Engel, P. & Terhorst, C. Responses to microbial challenges by SLAMF receptors. Front. Immunol. 7, 4 (2016).
pubmed: 26834746 pmcid: 4718992
Youn, J. I., Collazo, M., Shalova, I. N., Biswas, S. K. & Gabrilovich, D. I. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J. Leukoc. Biol. 91, 167–181 (2012).
doi: 10.1189/jlb.0311177 pubmed: 21954284 pmcid: 3250305
Lu, W. et al. Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer. EMBO Mol. Med. 13, e12798 (2021).
doi: 10.15252/emmm.202012798 pubmed: 33283987
Galon, J. & Bruni, D. Tumor Immunology and tumor evolution: intertwined histories. Immunity 52, 55–81 (2020).
doi: 10.1016/j.immuni.2019.12.018 pubmed: 31940273
Cremonesi, E. et al. Gut microbiota modulate T cell trafficking into human colorectal cancer. Gut 67, 1984–1994 (2018).
doi: 10.1136/gutjnl-2016-313498 pubmed: 29437871
Yu, A. I. et al. Gut microbiota modulate CD8 T cell responses to influence colitis-associated tumorigenesis. Cell Rep. 31, 107471 (2020).
doi: 10.1016/j.celrep.2020.03.035 pubmed: 32268087 pmcid: 7934571
Zhang, Y., Weng, Y., Gan, H., Zhao, X. & Zhi, F. Streptococcus gallolyticus conspires myeloid cells to promote tumorigenesis of inflammatory bowel disease. Biochem. Biophys. Res. Commun. 506, 907–911 (2018).
doi: 10.1016/j.bbrc.2018.10.136 pubmed: 30392911
Marvel, D. & Gabrilovich, D. I. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J. Clin. Invest. 125, 3356–3364 (2015).
doi: 10.1172/JCI80005 pubmed: 26168215 pmcid: 4588239
Chen, H. et al. METTL3 inhibits antitumor immunity by targeting m
Ramos-Sevillano, E., Moscoso, M., Garcia, P., Garcia, E. & Yuste, J. Nasopharyngeal colonization and invasive disease are enhanced by the cell wall hydrolases LytB and LytC of Streptococcus pneumoniae. PLoS ONE 6, e23626 (2011).
doi: 10.1371/journal.pone.0023626 pubmed: 21886805 pmcid: 3160309
Kang, X. et al. Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8
Luu, M. et al. Regulation of the effector function of CD8
doi: 10.1038/s41598-018-32860-x pubmed: 30258117 pmcid: 6158259
Louis, P., Hold, G. L. & Flint, H. J. The gut microbiota, bacterial metabolites and colorectal cancer. Nat. Rev. Microbiol. 12, 661–672 (2014).
doi: 10.1038/nrmicro3344 pubmed: 25198138
Wang, H. et al. The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer. Cell Metab. 34, 581–594 (2022).
doi: 10.1016/j.cmet.2022.02.010 pubmed: 35278352
Gur, C. et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 42, 344–355 (2015).
doi: 10.1016/j.immuni.2015.01.010 pubmed: 25680274 pmcid: 4361732
The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337 (2012).
Walker, M. A. et al. GATK PathSeq: a customizable computational tool for the discovery and identification of microbial sequences in libraries from eukaryotic hosts. Bioinformatics 34, 4287–4289 (2018).
doi: 10.1093/bioinformatics/bty501 pubmed: 29982281 pmcid: 6289130
Zou, Y. et al. 1,520 reference genomes from cultivated human gut bacteria enable functional microbiome analyses. Nat. Biotechnol. 37, 179–185 (2019).
doi: 10.1038/s41587-018-0008-8 pubmed: 30718868 pmcid: 6784896

Auteurs

Yali Liu (Y)

Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, CUHK Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong, China.

Chi Chun Wong (CC)

Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, CUHK Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong, China.

Yanqiang Ding (Y)

Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, CUHK Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong, China.

Mengxue Gao (M)

Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin, China.

Jun Wen (J)

Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, CUHK Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong, China.
ORCID: 0000-0002-6947-2087

Harry Cheuk-Hay Lau (HC)

Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, CUHK Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong, China.
ORCID: 0000-0003-3581-2909

Alvin Ho-Kwan Cheung (AH)

Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.

Dan Huang (D)

Department of Biology, School of Life Sciences, Southern University of Science and Technology, Shenzhen, China.
ORCID: 0000-0003-3022-5772

He Huang (H)

Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin, China.
ORCID: 0000-0003-3008-4869

Jun Yu (J)

Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, CUHK Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong, China. junyu@cuhk.edu.hk.
ORCID: 0000-0001-5008-2153

Classifications MeSH